Free Trial

Fractyl Health Q4 2023 Earnings Report

Fractyl Health logo
$1.90 -0.12 (-5.94%)
(As of 05:45 PM ET)

Fractyl Health EPS Results

Actual EPS
-$8.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Fractyl Health Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Fractyl Health Announcement Details

Quarter
Q4 2023
Time
N/A
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.

>> Register for the Workshop Now
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fractyl Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fractyl Health and other key companies, straight to your email.

About Fractyl Health

Fractyl Health (NASDAQ:GUTS), a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

View Fractyl Health Profile

More Earnings Resources from MarketBeat

Upcoming Earnings